<div id="readability-page-1"><div>NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 15, 2025, citing federal data and inspection reports, The New York Times published an article alleging that for-profit hospitals run by Encompass perform below average on key safety measures. The article reported that “Encompass owns many of the rehabs with worse rates of potentially preventable, unplanned readmissions to general hospitals” including 34 facilities which “Medicare rated as having statistically significantly worse rates of potentially preventable readmissions.” The article further described a number of “alarming mistakes” leading to fatalities of patients in the care of Encompass-owned facilities. Following publication of the article, Encompass’s stock price fell $12.39 per share, or 10.35%, to close at $107.28 per share on July 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETTBPQ00zTURnNE1ESTVJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETTBPQ00zTURnNE1ESTVJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2IyOTllYTgtODBlMC00MTViLWJkMGMtZTg1ZDZiYTQ1MmJlLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2IyOTllYTgtODBlMC00MTViLWJkMGMtZTg1ZDZiYTQ1MmJlLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

Pomerantz 律师事务所正在代表 Encompass Health Corporation（纽约证券交易所代码：EHC）的投资者调查有关潜在证券欺诈和非法商业行为的索赔。这一调查是基于《纽约时报》的一篇文章，该文章指控 Encompass 的营利性医院在安全措施方面表现不佳，导致其股价在 2025 年 7 月 15 日大幅下跌 10.35%，至每股 107.28 美元。鼓励投资者联系该事务所以获取有关加入集体诉讼的更多信息

投资者警报：Pomerantz 律师事务所代表 Encompass Health Corporation 的投资者进行索赔调查